Visual Impairment Risks of Long-Acting Insulin Analogues: FAERS Data Analysis

Overview

This study analyzed over 100,000 FAERS reports to compare visual impairment adverse events linked to insulin degludec, detemir, and glargine. Insulin glargine showed the strongest association with diabetic glaucoma, while degludec and detemir were primarily linked to diabetic retinopathy, with all three exhibiting early-onset patterns.

Background

Diabetes mellitus is a major global health issue with rising prevalence, often complicated by ocular morbidities such as diabetic retinopathy and glaucoma, which are leading causes of blindness. Long-acting insulin analogues—degludec, detemir, and glargine—are widely used basal insulins designed to maintain stable glycemic control. However, post-marketing surveillance suggests these agents may differ in their risk profiles for visual impairment adverse events, potentially due to their distinct pharmacological properties and effects on ocular tissue homeostasis. Understanding these risks is critical for optimizing ophthalmic monitoring during insulin therapy initiation.

Data Highlights

Key Findings

• All three long-acting insulins showed statistically significant signals for visual impairment adverse events in FAERS data.
• Insulin glargine had the strongest overall disproportionality signal (ROR=3.60) and was strongly associated with diabetic glaucoma (ROR=50.36).
• Insulin degludec and detemir were primarily linked to diabetic retinopathy rather than glaucoma.
• Over 60% of visual impairment reports involved female patients, with 93% originating from the United States.
• Higher body weight appeared as a potential protective factor against visual impairment, though this may be confounded by diabetes type differentiation limitations.
• Weibull analysis indicated an early-onset pattern for visual impairment across all insulins, with degludec having the shortest median time-to-onset of 23.6 days.

Clinical Implications

Clinicians should be aware of the differential risks of visual impairment associated with specific long-acting insulin analogues when initiating basal insulin therapy. Early ophthalmic monitoring is advisable, especially within the first month of treatment, to detect and manage potential adverse ocular events promptly. Individualized risk assessment considering patient characteristics such as body weight and diabetes type may further optimize monitoring strategies.

Conclusion

This pharmacovigilance study highlights distinct visual impairment risk profiles and early-onset patterns among insulin degludec, detemir, and glargine, underscoring the need for tailored ophthalmic surveillance during basal insulin initiation in diabetic patients.

References

1. International Diabetes Federation 2021 -- Diabetes Prevalence and Projections
2. Rosenstock et al. 2015 -- Retinopathy Risks with Insulin Glargine vs NPH
3. Larose et al. 2019 -- Long-Acting Insulin Safety in UK CPRD Cohort